Overview

Adherence to Otezla

Status:
Not yet recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
Most people with psoriasis have very limited disease, yet that disease may still have a large impact on their lives. While limited psoriasis may be amenable to topical treatment, patients are exceptionally poorly adherent to topical treatment, especially over the long run.
Phase:
Early Phase 1
Details
Lead Sponsor:
Wake Forest University Health Sciences
Collaborator:
Amgen
Treatments:
Apremilast
Thalidomide